Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck (MRK) ended the recent trading session at $92.25, demonstrating a +1.84% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 1.59%.

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday. The ...

NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

Berenberg analyst Luisa Hector lowered the firm’s price target on Merck (MRK) to $115 from $125 and keeps a Buy rating on the shares. Merck ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Glancy Prongay & Murray LLP reminds investors of the upcoming April 14, 2025 deadline to file a lead plaintiff motion in the class action filed on ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...